Filing
3rd Quarter - Report
Lobbying activity
3
IRA, drug pricing in federal programs, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency
Medicare coverage and reimbursement issues, Medicare Part B reimbursement, transparency, prescription drug pricing and access, drug pricing in federal programs
federal budget issues